Table 7 Predictors of survival of patients with lean NAFLD
Univariate | Multivariate | |||||
|---|---|---|---|---|---|---|
HR | (95% CI) | P value | HR | (95% CI) | P value | |
Sex | ||||||
Male | 1.47 | (0.45–4.83) | 0.526 | |||
Female | 1 | |||||
History of liver cancer | ||||||
Yes | 15.89 | (4.62–54.62) | < 0.01 | 7.17 | (1.76–29.23) | < 0.01 |
No | 1 | |||||
History of non-liver malignancy | ||||||
Yes | 2.89 | (0.60–13.99) | 0.186 | |||
No | 1 | |||||
Dyslipidemia | ||||||
No | 3.88 | (0.50–30.35) | 0.196 | |||
Yes | 1 | |||||
Hypertension | ||||||
Yes | 1.33 | (0.39–4.53) | 0.653 | |||
No | 1 | |||||
Hyperuricemia | ||||||
No | 25,570,000 | (0.00-∞) | 0.998 | |||
Yes | 1 | |||||
Smoking | ||||||
No | 1.09 | (0.23–5.12) | 0.916 | |||
Yes | 1 | |||||
Gamma-glutamyl transpeptidase (IU/L) | ||||||
≥ 71 | 1.18 | (0.36–3.87) | 0.786 | |||
< 71 | 1 | |||||
Hemoglobin (g/dL) | ||||||
≤ 14.5 | 1.76 | (0.51–6.01) | 0.369 | |||
> 14.5 | 1 | |||||
Ferritin (ng/mL) | ||||||
≥ 180 | 1.33 | (0.40–4.40) | 0.640 | |||
< 180 | 1 | |||||
NAFLD fibrosis score | ||||||
≥ − 1.455 | 31.43 | (3.90–253.2) | < 0.01 | 12.87 | (1.35–122.30) | 0.026 |
< − 1.455 | 1 | |||||
PNPLA3 rs738409 | ||||||
GG | 2.55 | (0.61–10.73) | 0.202 | |||
Non GG | 1 | |||||
TM6SF2 rs58542926 | ||||||
CC | 2.19 | (0.27–17.82) | 0.463 | |||
Non CC | 1 | |||||
HSD17B13 rs6834314 | ||||||
Non AA | 1.03 | (0.252–4.066) | 0.986 | |||
AA | 1 | |||||